Skip to main content

Table 2 Clinical Features of the Three Study Cohorts with Case Matched

From: Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study

 None
(n = 54)
Anti-TNF
(n = 74)
Vedolizumab
(n = 25)
p
Gender (M/F)29:2535:3913:120.76
Age at surgery (years)35 (23–49)30 (21–45)31 (22–47)0.31
BMI (kg/m2)23.3(19–28)22.7(19–26)21.1(19–26)0.15
Preoperative weight loss (> 10 lbs) a17 (35)23 (37)10 (43)0.79
Missing6(11)11(15)2(8)0.63
Disease duration (mos)61 (24–152)53 (20–195)60 (24–148)0.46
Smoking0.74
Never43 (80)59 (80)21 (84) 
Prior8 (15)13 (17)4 (16) 
Current3 (5)2 (3)0 
Disease extent0.89
E2 Left-sided colitis7 (13)9 (12)4 (16) 
E3 Pancolitis47 (87)65 (88)21 (84) 
Disease activity0.714
Acute3(5.6)2(2.7)1(4.0) 
Chronic51(94.4)73(2.7)24(4.0) 
Medication history
Steroids34 (68)48 (68)18 (72)0.92
6-MP or MTX24 (45)62 (84)20 (80)0.001
Operation type
open16(30)19(26)6(16)0.83
laparoscopy38(70)55(74)19(76) 
Operation performed
Total abdominal colectomy
+end stoma
15 (28)15 (20)5 (20)0.57
Protectomy + IPAA with ileostomy39 (72)59 (80)20 (80) 
Ileostomy repair46(85)60(81)19(76)0.61
Preoperative labs
Leukocyte (×103/uL)8.9 (6.5–12.4)9 (6.4–13)9.8 (6.9–12)0.79
Platelet (×103/uL)360 (281–475)350 (280–459)340 (274–487) 
Albumin (g/dL)3.6 (3.3–4.0)3.6 (3.2–4.1)3.9 (3.6–4.2)0.87
0.25
  1. All values expressed as median (range) or n (%)
  2. BMI body mass index, 6-MP 6-mercaptopurine, MTX methotrexate, IPAA ileal pouch-anal anastomosis, TNF tumor necrosis factor
  3. a19 cases with data missing